Business Context and Reporting Period
Spruce Biosciences, Inc. (SPRB) filed a Form 8-K on January 5, 2023, reporting a material definitive agreement and providing a corporate update. The company is a biopharmaceutical firm focused on developing treatments for congenital adrenal hyperplasia (CAH) using its product candidate, tildacerfont.
Key Financial Metrics
- Liquidity: As of December 31, 2022, the company estimated its cash, cash equivalents, and investments at approximately $79 million. This figure is unaudited and preliminary.
- Revenue: The filing does not provide historical revenue figures. However, the new agreement includes an upfront payment of $15.0 million.
- Debt: The filing text does not provide specific debt values.
- Profit/Margins: The filing text does not provide profit or margin data.
Material Changes and Agreements
On January 5, 2023, Spruce entered into a Collaboration and License Agreement with Kaken Pharmaceutical Co., LTD. Key terms include:
- Geography: Kaken received exclusive rights to develop, manufacture, and commercialize tildacerfont for CAH in Japan. Spruce retains rights in all other geographies.
- Financial Terms:
- Upfront payment: $15.0 million.
- Potential milestone payments: Up to approximately $65 million (at current exchange rates) based on development, regulatory, and sales milestones in Japan.
- Royalties: Double-digit percentages up to the mid-twenties on annual net sales in Japan.
- Supply: Spruce will supply clinical and commercial drug requirements, with Kaken paying a specified purchase price for Company-manufactured units.
- Right of First Negotiation: Kaken has a right of first negotiation for tildacerfont in China, South Korea, and other specified Southeast Asian countries, as well as for non-CAH indications.
Outlook, Management Commentary, and Risks
Clinical Program Updates: The company announced protocol changes to its Phase 2 open-label clinical trial for tildacerfont in children with CAH to enhance data collection for a potential Phase 3 registrational trial. Changes include:
- Extending the study length from 2 weeks to 12 weeks, with a potential 2-year open-label extension.
- Lowering the minimum age eligibility from 6 years to 2 years.
- Collecting additional pharmacokinetic (PK) and pharmacodynamic (PD) data, including androstenedione (A4) reduction and glucocorticoid (GC) reduction data.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include the uncertainty of clinical trial results, the ability to obtain regulatory approval, funding sufficiency, intellectual property protection, and macroeconomic impacts. The $79 million cash estimate is subject to final financial closing procedures.
Investor Verification Checklist
- Verify the final audited cash position as of December 31, 2022, once the financial closing is complete.
- Monitor the execution of the clinical supply agreement with Kaken, required within 90 days of the effective date.
- Track the progress of the amended Phase 2 clinical trial, specifically the enrollment of the new 2-to-5-year-old cohort and the 12-week data readout.
- Review the specific milestones and sales thresholds required to trigger the $65 million in potential payments.
- Assess the impact of the $15 million upfront payment on the company's runway and burn rate.